Vagal nerve stimulation reverses aberrant dopamine system function in the methylazoxymethanol acetate rodent model of schizophrenia

Journal of Neuroscience

Volumn 34, Issue 28, 2014, Pages 9261-9267

  Perez, Stephanie M ^a   Carreno, Flavia R ^a   Frazer, Alan ^a,b   Lodge, Daniel J ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Dopamine; Hippocampus; Schizophrenia; Vagal nerve stimulation

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; VAGUS NERVE STIMULATION;

DOPAMINE; HIPPOCAMPUS; SCHIZOPHRENIA; VAGAL NERVE STIMULATION;

ACTION POTENTIALS; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; HIPPOCAMPUS; HUMANS; MALE; METHYLAZOXYMETHANOL ACETATE; NEUROTOXINS; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; TREATMENT OUTCOME; VAGUS NERVE STIMULATION;

EID: 84903971410     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0588-14.2014     Document Type: Article

References (51)

1. Abi-DarghamA (2004) Dowe still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 7:S1-S5. CrossRef
2. Akbarian S., Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, BunneyWEJr, Jones EG (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Archives of General Psychiatry 52:258-266. CrossRef Medline
3. Akil M., Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA (1999) Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156: 1580-1589. Medline
4. Bhugra D. (2005) The global prevalence of schizophrenia. PLoS Med 2: e151. CrossRef Medline
5. Breier A., Buchanan RW, Elkashef A, Munson RC, Kirkpatrick B, Gellad F (1992) Brain morphology and schizophrenia: a magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch Gen Psychiatry 49:921-926. CrossRef Medline
6. Carreno F. R, Frazer A (2014) Activation of signaling pathways downstream of the brain-derived neurotrophic factor receptor, TrkB, in the rat brain by vagal nerve stimulation and antidepressant drugs. Int J Neuropsychopharmacol 17:247-258. CrossRef Medline
7. Curet O., de Montigny C (1988a) Electrophysiological characterization of adrenoceptors in the rat dorsal hippocampus: I. Receptors mediating the effect of microiontophoretically applied norepinephrine. Brain Res 475: 35-46. CrossRef Medline
8. Curet O., de Montigny C (1988b) Electrophysiological characterization of adrenoceptors in the rat dorsal hippocampus: II. Receptors mediating the effect of synaptically released norepinephrine. Brain Res 475:47-57. CrossRef Medline
9. Elger G., Hoppe C, Falkai P, Rush AJ, Elger CE (2000) Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res 42: 203-210. CrossRef Medline
10. Furmaga H., Carreno FR, Frazer A (2012) Vagal nerve stimulation rapidly activates brain-derived neurotrophic factor receptor TrkB in rat brain. PLoS One 7:e34844. CrossRef Medline
11. George M. S, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, Howland R., Kling MA, Moreno F, Rittberg B, Dunner D, Schwartz T, Carpenter L., Burke M, Ninan P, Goodnick P (2005) A one-year comparison of vagus nerve stimulation with treatment as usual for treatmentresistant depression. Biol Psychiatry 58:364-373. CrossRef Medline
12. Gill K. M, Lodge DJ, Cook JM, Aras S, Grace AA (2011) A novel alpha5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology 36:1903-1911. CrossRef Medline
13. Grace A. A, Bunney BS, Moore H, Todd CL (1997) Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 20:31-37. CrossRef Medline
14. Groves D. A, Brown VJ (2005) Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. Neurosci Biobehav Rev 29:493-500. CrossRef Medline
15. Harden C. L, Pulver MC, Ravdin LD, Nikolov B, Halper JP, Labar DR (2000) A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav 1:93-99. CrossRef Medline
16. Harrison P. J (1999) The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 122:593-624. CrossRef Medline
17. Hashimoto T., Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, Sampson AR, Lewis DA (2003) Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 23:6315-6326. Medline
18. Heckers S. (2001) Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus 11:520-528. CrossRef Medline
19. Heckers S., Rauch SL, Goff D, Savage CR, Schacter DL, Fischman AJ, AlpertNM (1998) Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1:318-323. CrossRef Medline
20. Henry T. R, Bakay RA, Votaw JR, Pennell PB, Epstein CM, Faber TL, Grafton ST, Hoffman JM (1998) Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation. Epilepsia 39:983-990. CrossRef Medline
21. Henry T. R, Bakay RA, Pennell PB, Epstein CM, Votaw JR (2004) Brain blood-flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: II. prolonged effects at high and low levels of stimulation. Epilepsia 45:1064-1070. CrossRef Medline
22. Howes O. D, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 35: 549-562. CrossRef Medline
23. Jones B. E, Moore RY (1977) Ascending projections of the locus coeruleus in the rat: II. Autoradiographic study. Brain Res 127:25-53. Medline
24. Kraus T., Hösl K, Kiess O, Schanze A, Kornhuber J, Forster C (2007) BOLD fMRI deactivation of limbic and temporal brain structures and mood enhancing effect by transcutaneous vagus nerve stimulation. J Neural Transm 114:1485-1493. CrossRef Medline
25. Kuba R., Brázdil M, Kalina M, Procházka T, Hovorka J, Nezádal T, Hadac J, Brozová K., Sebronová V, Komárek V, Marusic P, Oslejsková H, Zárubová J, Rektor I (2009) Vagus nerve stimulation: longitudinal follow-up of patients treated for 5 years. Seizure 18:269-274. CrossRef Medline
26. Laruelle M., Abi-Dargham A (1999) Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 13: 358-371. CrossRef Medline
27. Lieberman, Lesser M, Johns C, Pollack S, Saltz B, Kane J (1988) Pharmacologic studies of tardive dyskinesia. J Clin Psychopharmacol 8:57S-63S. CrossRef Medline
28. Lieberman J. A, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223. CrossRef Medline
29. Lodge D. J (2013) The MAM rodent model of schizophrenia. Curr Protoc Neurosci 9:43. CrossRef Medline
30. Lodge D. J, Grace AA (2007) Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci 27:11424-11430. CrossRef Medline
31. Lodge D. J, Grace AA (2009) Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res 204:306-312. CrossRef Medline
32. Lodge D. J, Grace AA (2011) Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci 32:507-513. CrossRef Medline
33. Manta S., El Mansari M, Debonnel G, Blier P (2013) Electrophysiological and neurochemical effects of long-term vagus nerve stimulation on the rat monoaminergic systems. Int J Neuropsychopharmacol 16:459-470. CrossRef Medline
34. Medoff D. R, Holcomb HH, Lahti AC, Tamminga CA (2001) Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 11:543-550. CrossRef Medline
35. Moore H., Jentsch JD, Ghajarnia M, Geyer MA, GraceAA (2006) Aneurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry 60:253-264. CrossRef Medline
36. Morris G. L 3 rd, MuellerWM (1999) Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy: The Vagus Nerve Stimulation Study Group E01-E05. Neurology 53:1731-1735. CrossRef Medline
37. Nahas Z., Marangell LB, Husain MM, Rush AJ, Sackeim HA, Lisanby SH, Martinez J. M, George MS (2005) Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 66:1097-1104. CrossRef Medline
38. Nemeroff C. B, Mayberg HS, Krahl SE, McNamara J, Frazer A, Henry TR, George MS, Charney DS, Brannan SK (2006) VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology 31:1345-1355. CrossRef Medline
39. Newcomer J. W (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19:1-93. CrossRef Medline
40. Perez S. M, Lodge DJ (2012) Aberrant dopamine D2-like receptor function in a rodent model of schizophrenia. J Pharmacol Exp Ther 343:288-295. CrossRef Medline
41. Perez S. M, Lodge DJ (2013) Hippocampal interneuron transplants reverse aberrant dopamine system function and behavior in a rodent model of schizophrenia. Mol Psychiatry 18:1193-1198. CrossRef Medline
42. Perez S. M, Shah A, Asher A, Lodge DJ (2013) Hippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia. Int J Neuropsychopharmacol 16:1331-1339. CrossRef Medline
43. Roosevelt R. W, Smith DC, Clough RW, Jensen RA, Browning RA (2006) Increased extracellular concentrations of norepinephrine in cortex and hippocampus following vagus nerve stimulation in the rat. Brain Res 1119:124-132. CrossRef Medline
44. Rush A. J, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R., Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg A. A, Husain MM, Ginsberg D, Cooke RG (2005a) Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 58:347-354. CrossRef Medline
45. Rush A. J, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P., Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F., Schwartz T, Conway C, Burke M, Barry JJ (2005b) Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 58:355-363. CrossRef Medline
46. Saha S., Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2:e141. CrossRef Medline
47. Schachter S. C (2002) Vagus nerve stimulation therapy summary: five years after FDA approval. Neurology 59: S15-20. CrossRef Medline
48. Schobel S. A, Kelly MA, Corcoran CM, Van Heertum K, Seckinger R, Goetz R, Harkavy-Friedman J., Malaspina Da (2009) Anterior hippocampal and orbitofrontal cortical structural brain abnormalities in association with cognitive deficits in schizophrenia. Schizophr Res 114: 110-118. CrossRef Medline
49. Schobel S. A, LewandowskiNM, Corcoran CM, Moore H, Brown T, Malaspina D, Small SA (2009) Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry 66:938-946. CrossRef Medline
50. Shah A., Lodge DJ (2013) A loss of hippocampal perineuronal nets produces deficits in dopamine system function: relevance to the positive symptoms of schizophrenia. Transl Psychiatry 3:e215. CrossRef Medline
51. Tamminga C. A, Stan AD, Wagner AD (2010) The hippocampal formation in schizophrenia. Am J Psychiatry 167:1178-1193. CrossRef Medline